Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 30 min ago
PreprintCC BYbioRxiv

Olfactory neuroepithelium biomarker platform: a proof from Alzheimer's disease

  • K. Ishizuka
  • G. Shang
  • S. Malik
  • C. Doty
  • S. Dave
  • N. Rowan
  • Y. Lema
  • A. Lane
  • A. Sawa1
  1. 1Johns Hopkins School of Medicine
Read full textPDFDOICite

Abstract

Unlike other diseases where target organs for biopsy are accessible, surrogate platforms are warranted for biomarkers of neuropsychiatric disorders due to the inaccessibility of the brain. We demonstrate a non-invasive platform combining a nasal soft-brush swab with single-cell Western blotting for neuron-specific protein analysis. Applied to Alzheimer's disease targeting phosphorylated tau, this demonstrated superior diagnostic capacity compared with blood-based approaches, indicating that the olfactory neuroepithelium is a sensitive biomarker platform.

Related

  1. Hydrogen gas and olfactory dysfunction in Alzheimer’s disease: the Hydrogen–Olfactory–Limbic hypothesis
    Ligao Bao, Dunfu Eer
    Frontiers in aging neurosciencePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Olfactory Function in Preclinical Alzheimer's Disease: A Multi-Cohort Study
    B. Jobin, Y. Salman, K. Bouchoucha +13
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  3. Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer’s disease
    Jinshu Liang, Zongtang Xu, Ziting Zhu +7
    Translational PsychiatryPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref
  4. Functional Deficits and Diffusion Tensor Magnetic Resonance Imaging of the Olfactory and Vision Systems in the Alzheimer’s Disease Model of Aging GluN3A Knockout Mice
    Ling Wei, Michael Qize Jiang, Yingying Zhao +7
    CellsPeer-reviewedCC BY 4.0PhysiologyCrossref
  5. SPLASH: a benchtop platform for accessible, ultrasensitive quantification of plasma biomarkers in Alzheimer’s disease
    Noah Elder, Hien Nguyen, Jason Wan +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref

Cite

BibTeXRIS
BibTeX
@misc{ishizuka2026olfactory,
  title = {{Olfactory neuroepithelium biomarker platform: a proof from Alzheimer's disease}},
  author = {K. Ishizuka and G. Shang and S. Malik and C. Doty and S. Dave and N. Rowan and Y. Lema and A. Lane and A. Sawa},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.18.759991},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.18.759991v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Olfactory neuroepithelium biomarker platform: a proof from Alzheimer's disease
AU  - K. Ishizuka
AU  - G. Shang
AU  - S. Malik
AU  - C. Doty
AU  - S. Dave
AU  - N. Rowan
AU  - Y. Lema
AU  - A. Lane
AU  - A. Sawa
PY  - 2026
DA  - 2026/10/18
PB  - bioRxiv
DO  - 10.64898/2026.10.18.759991
UR  - https://www.biorxiv.org/content/10.64898/2026.10.18.759991v1
AB  - Unlike other diseases where target organs for biopsy are accessible, surrogate platforms are warranted for biomarkers of neuropsychiatric disorders due to the inaccessibility of the brain. We demonstrate a non-invasive platform combining a nasal soft-brush swab with single-cell Western blotting for neuron-specific protein analysis. Applied to Alzheimer's disease targeting phosphorylated tau, this demonstrated superior diagnostic capacity compared with blood-based approaches, indicating that the olfactory neuroepithelium is a sensitive biomarker platform.
SN  - 2692-8205
ER  -